We have located links that may give you full text access.
Pretreatment neutrophil-to-lymphocyte ratio predicts worse survival outcomes and advanced tumor staging in patients undergoing radical cystectomy for bladder cancer.
Asian Journal of Urology 2017 October
OBJECTIVE: To determine the role of neutrophil-to-lymphocyte ratio (NLR) in prognosticating survival outcomes in patients with advanced/metastatic urothelial bladder cancer.
METHODS: We retrospectively reviewed 84 patients undergoing radical cystectomy (RC) for UCB from January 2002 to June 2012. NLR was computed (median: 5 days) prior to surgery. No patients received neoadjuvant chemotherapy. NLR was analyzed as a continuous variable and a cut-off point of 2.7 was obtained, with a statistical receiver operating characteristics of 0.74. Kaplan-Meier curves, multivariate Cox proportional hazard and logistics regression models were used to predict NLR association with survival outcomes.
RESULTS: The median follow-up period was 30.1 months (range: 3.2-161.7) owing to high recurrence rate and subsequent mortalities, compared to the median 64.7 months in patients alive at the end of study period. NLR ≥2.7 was associated with worse survival outcomes (5-year disease-specific survival: 22% vs 58%, p = 0.017, 95%CI: 1.193-6.009; 5-year overall survival: 23% vs 60%, p = 0.008, 95%CI: 1.322-6.147). Furthermore, on multivariate analyses, higher NLR was independently associated with higher recurrence rate ( p = 0.007, HR =6.999, 95%CI: 1.712-28.606), higher T staging ( p = 0.021, HR = 3.479, 95%CI: 1.212-9.990) and lymph node involvement ( p = 0.009, HR = 4.534, 95%CI: 1.465-14.034).
CONCLUSION: This study suggests that NLR can be an inexpensive novel factor for patients risk stratification pre-operatively. This improves patient counseling and identifies patients who may benefit from multimodal treatment.
METHODS: We retrospectively reviewed 84 patients undergoing radical cystectomy (RC) for UCB from January 2002 to June 2012. NLR was computed (median: 5 days) prior to surgery. No patients received neoadjuvant chemotherapy. NLR was analyzed as a continuous variable and a cut-off point of 2.7 was obtained, with a statistical receiver operating characteristics of 0.74. Kaplan-Meier curves, multivariate Cox proportional hazard and logistics regression models were used to predict NLR association with survival outcomes.
RESULTS: The median follow-up period was 30.1 months (range: 3.2-161.7) owing to high recurrence rate and subsequent mortalities, compared to the median 64.7 months in patients alive at the end of study period. NLR ≥2.7 was associated with worse survival outcomes (5-year disease-specific survival: 22% vs 58%, p = 0.017, 95%CI: 1.193-6.009; 5-year overall survival: 23% vs 60%, p = 0.008, 95%CI: 1.322-6.147). Furthermore, on multivariate analyses, higher NLR was independently associated with higher recurrence rate ( p = 0.007, HR =6.999, 95%CI: 1.712-28.606), higher T staging ( p = 0.021, HR = 3.479, 95%CI: 1.212-9.990) and lymph node involvement ( p = 0.009, HR = 4.534, 95%CI: 1.465-14.034).
CONCLUSION: This study suggests that NLR can be an inexpensive novel factor for patients risk stratification pre-operatively. This improves patient counseling and identifies patients who may benefit from multimodal treatment.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app